BioSpace News Archive

According to Emergen Research, the global nutrigenomics market size was USD 389.4 Million in 2020 and is expected to reach USD 1,289.7 Million in 2028 and register a revenue CAGR of 16.2% during the forecast period, 2021-2028.

Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced that the National Medical Products Administration (NMPA) of China has granted approval of the company’s monoclonal neutralizing antibody (mAb) therapy.

The global whole exome sequencing market revenue growth has gained momentum over the recent past due to many favorable factors.

India Globalization Capital, Inc. (IGC) today announces preliminary results for its exploratory endpoints from its Phase 1 IGC-AD1 clinical trial. IGC-AD1 is a proprietary cannabis-based investigational new drug candidate for patients suffering from Alzheimer’s disease.

Seagen Inc. (Nasdaq:SGEN) today announced the presentation of new data from exploratory analyses from the pivotal HER2CLIMB trial showing that improvement in overall survival (OS) was maintained after an additional 15.6 months of follow-up when TUKYSA® (tucatinib) was combined with trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer (MBC) who had stable or active brain metastases.

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases, such as ALS, Alzheimer’s and Parkinson’s disease, today announced the pricing of its initial public offering of 2,000,000 units.

Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced new clinical data for the HER2-targeted bispecific antibody, zanidatamab, in heavily pretreated HER2-positive breast cancer.

Bobby Sheng, chairman of Bora Pharmaceuticals, announced a partnership with Taishin Healthcare Limited Partnership at the 2021 Biotech Investor Forum, whereby the two parties will jointly invest up to NT$3 billion to target forward-looking contract development and manufacturing organizations and contract research organizations, in response to the development trend that is taking place worldwide.

Mispro Biotech Services, North America’s leading contract vivarium organization with locations in all major U.S. biotech hubs, has announced expansion in Research Triangle Park with a new facility set to open in early 2022.

Premia Spine today announced the appointment of three new advisors to its board of directors.